Company Overview of Melinta Therapeutics, Inc.
Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.
300 George Street
New Haven, CT 06511-6663
Founded in 2000
Key Executives for Melinta Therapeutics, Inc.
Executive Vice President of Research and Development
Senior Vice President of Corporate Development and Strategy
Compensation as of Fiscal Year 2014.
Melinta Therapeutics, Inc. Key Developments
Melinta Therapeutics and Hartford Hospital Announces Vitro Results from an Investigator-Sponsored Study
Sep 6 14
Melinta Therapeutics and Hartford Hospital announced in vitro results from an investigator-sponsored study that highlight delafloxacin's activity in low pH environments, which are characteristic of infection sites. Delafloxacin is an investigational fluoroquinolone under development for acute bacterial skin and skin structure infections and uncomplicated gonorrhea. In this study, which was conducted by Drs. Wonhee So, Jared Crandon and David Nicolau in the Center for Anti-Infective Research and Development at Hartford Hospital, urine samples were collected from patients suspected of having a urinary tract infection (UTI). Greater than 70% of these samples were acidic, with pH measured at or below 6.5. In all patient samples tested, delafloxacin was shown to be active against Escherichia coli and Klebsiella pneumoniae, two pathogens that are frequently associated with complicated UTIs. Importantly, in the acidic samples (pH 5.0-6.0), delafloxacin's activity was found to be one to threefold greater than in normal or basic samples. Complete results from this study are being presented at the 54th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an American Society for Microbiology meeting. ICAAC is being held September 5, 2014 - September 9, 2014 at the Walter E. Washington Convention Center in Washington, DC.
Melinta Therapeutics Announces Results of a Phase 1 Study of Delafloxacin
Sep 6 14
Melinta Therapeutics announced results of a Phase 1 study of delafloxacin, an investigational fluoroquinolone, in healthy adults that confirm a pharmacokinetic (PK) profile supportive of a single oral dose in the treatment of patients with uncomplicated gonorrhea. Specifically, results from this study of 20 healthy adults demonstrated that the mean time to peak plasma concentration following administration of a single 900mg dose of delafloxacin was approximately 1.4 hours, with a half-life of approximately 18 hours. Most common side effects were diarrhea, nausea and epistaxis (nosebleed). Delafloxacin is an investigational fluoroquinolone antibiotic with in vitro activity against both Gram negative and Gram positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Complete results from this study are being presented at the 54th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an American Society for Microbiology meeting. ICAAC is being held September 5, 2014 - September 9, 2014 at the Walter E. Washington Convention Center in Washington, DC.
Melinta Therapeutics Appoints Christopher Kiritsy to the Board of Directors
Aug 14 14
Melinta Therapeutics announced the appointment of Christopher Kiritsy to the company’s Board of Directors. Mr. Kiritsy is currently president, chief executive officer and director of Arisaph Pharmaceuticals, Inc. Mr. Kiritsy also currently serves as chairman of the Board of Directors of Avaxia Biologics. Mr. Kiritsy has over two decades of business and technical experience from senior management positions in corporate management, finance, research and development, and business development. Under Mr. Kiritsy’s leadership, Arisaph has evolved into a clinical development enterprise with a rich research pipeline.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 10, 2014